CAGRILINITIDE

Cagrilinitide (or “Cagri”) is a long-acting, lipidated, albumin-binding amylin agonist that targets both amylin and calcitonin receptors. It is used in the treatment of obesity, either on its own or in combination with GLP-1 receptor agonists. Amylin is co-secreted with insulin from pancreatic beta cells and regulates appetite, satiety, gastric emptying, and glucose control.

Combining Cagrilinitide with a GLP-1 like Semaglutide has a synergistic effect, amplifying weight loss beyond what either peptide achieves independently. Other benefits include improved circulation, reduced blood pressure, enhanced bone-building activity, and vasodilation.

Possible Side Effects

Injection site reaction (redness, swelling, itching, hives)
Nausea
Vomiting
Constipation
Fatigue
Headache
Diarrhea
Heartburn
Gallbladder stones (rare)

Contraindications

Do not use if you are pregnant or breastfeeding

Reconstitution

ADMINISTRATION METHOD: Subcutaneous Administration

TIMING: Once per week, always on the same day. Take 3-4 days after GLP injection or on the day you start to feel the most hunger coming back.

CYCLE LENGTH: 8 weeks followed by a 4-8 week washout period. Do not use for more than 12 weeks consecutively.

VIAL SIZE: 5mg

BAC WATER: 2mL

DOSING:

Week 1: 8 units (200mcg)
Week 2: 16 units (400mcg)
Wee 3: 30 units (750mcg)
Week 4: 48 units (1.2mg)
Week 5: 68 units (1.7mg)
Week 6: 88 units (2.2mg)

(Once you find which dose works best for appetite suppression without side effects, stay at that dose. Do not increase unless you are not getting any appetite suppression)